Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery
Advanced healthcare materials
; : e2202590, 2023.
Article
in English
| EMBASE | ID: covidwho-2232696
ABSTRACT
mRNA-based therapy has emerged as the most promising nucleic acid therapy in the fight against COVID-19. However, a safe and efficacious systemic delivery remains a challenge for mRNA therapy. Lipid nanoparticles (LNPs) are currently widely used in mRNA delivery vehicles. Here, series of ionizable LNPs are rationally designed. YK009-LNP is an optimal delivery platform to carry mRNA. YK009-LNP exhibited higher mRNA delivery efficiency, a more favorable biodistribution pattern, and better safety than the approved MC3-LNP. In addition, mRNA encoding SARS-CoV-2 Omicron receptor binding domain protein was synthesized, and intramuscular administration of mice with YK009-LNP-Omicron mRNA induced a robust immune response and immune protective effect. Our study provides a novel mRNA delivery vehicle with more powerful delivery efficiency and better safety than the approved LNPs. This article is protected by copyright. All rights reserved.
ionizable lipid; lipid nanoparticles; mRNA delivery; mRNA vaccine; SARS-CoV-2 Omicron variant; animal experiment; article; controlled study; immune response; intramuscular drug administration; ionization; male; mouse; nonhuman; protein domain; receptor binding; SARS-CoV-2 Omicron; transcription initiation; lipid; lipid nanoparticle; messenger RNA; RNA vaccine
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Variants
Language:
English
Journal:
Advanced healthcare materials
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS